AAAAAA

   
Results: 1-25 | 26-50 | 51-59
Results: 26-50/59
Molecular evidence linking primary cancer of the Fallopian tube to BRCA1 germline mutations
Authors: Zweemer, RP van Diest, PJ Verheijen, RHM Ryan, A Gille, JJP Sijmons, RH Jacobs, IJ Menko, FH Kenemans, P
Citation: Rp. Zweemer et al., Molecular evidence linking primary cancer of the Fallopian tube to BRCA1 germline mutations, GYNECOL ONC, 76(1), 2000, pp. 45-50
Sentinel node detection in cervical cancer
Authors: Verheijen, RHM Pijpers, R van Diest, PJ Burger, CW Buist, MR Kenemans, P
Citation: Rhm. Verheijen et al., Sentinel node detection in cervical cancer, OBSTET GYN, 96(1), 2000, pp. 135-138
Clinical Synthesis Conference. Hormone replacement therapy (Reprinted fromThe Lancet, vol 354, pg 152-155, 1999)
Authors: Grant, C Gray, A Paoletti, R Thornton, H von Kleist, S Beral, V Burger, H Creasman, W Delman, P Kenemans, P Leake, RE Meade, TW Skoog, I Andrews, WC Autier, P Birkhauser, M Fugh-Berman, A Bush, T Calle, E Franceschi, S Holmberg, L Stampfer, M Trimble, E Duffy, S Robertson, C Walker, AM Boyle, P Benagiano, G Horton, R Radda, G Sharp, D Walker, AM Cucinotta, S Castelli, M Manenti, S Monticelli, C Kahle, M Russell-Edu, W Sabatini, C Veronesi, U
Citation: C. Grant et al., Clinical Synthesis Conference. Hormone replacement therapy (Reprinted fromThe Lancet, vol 354, pg 152-155, 1999), INT J GYN O, 70(2), 2000, pp. 305-311
Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1peptides and N-acetylgalactosamine (GalNAc) peptides
Authors: von Mensdorff-Pouilly, S Petrakou, E Kenemans, P van Uffelen, K Verstraeten, AA Snijdewint, FGM van Kamp, GJ Schol, DJ Reis, CA Price, MR Livingston, PO Hilgers, J
Citation: S. Von Mensdorff-pouilly et al., Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1peptides and N-acetylgalactosamine (GalNAc) peptides, INT J CANC, 86(5), 2000, pp. 702-712
Clinical equivalence of intranasal and oral 17 beta-estradiol for postmenopausal symptoms
Authors: Mattsson, LA Christiansen, C Colau, JC Palacios, S Kenemans, P Bergeron, C Chevallier, O Von Holst, T Gangar, K
Citation: La. Mattsson et al., Clinical equivalence of intranasal and oral 17 beta-estradiol for postmenopausal symptoms, AM J OBST G, 182(3), 2000, pp. 545-552
Hormonal prevention of breast cancer: proposal for a change in paradigm
Authors: Hesch, RD Kenemans, P
Citation: Rd. Hesch et P. Kenemans, Hormonal prevention of breast cancer: proposal for a change in paradigm, BR J OBST G, 106(10), 1999, pp. 1006-1018
An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma
Authors: Davies, Q Perkins, AC Roos, JC Molthoff, CFM Verheijen, RHM Frier, M Kenemans, P Broadhead, T Sopwith, M Symonds, EM
Citation: Q. Davies et al., An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma, BR J OBST G, 106(1), 1999, pp. 31-37
Postmenopausal oestradiol-dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women
Authors: Mijatovic, V Kenemans, P van der Mooren, MJ Emeis, JJ van Baal, WM Peters-Muller, ER Stehouwer, CDA
Citation: V. Mijatovic et al., Postmenopausal oestradiol-dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women, FIBRINOL PR, 13(4-5), 1999, pp. 177-183
I-131-labelled chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study
Authors: van Zanten-Przybysz, I Molthoff, CFM Visser, GWM Verheijen, RMH Plaizier, MABD Pijpers, R Kenemans, P Roos, JC
Citation: I. Van Zanten-przybysz et al., I-131-labelled chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study, TUMOR TARG, 4(3), 1999, pp. 179-188
Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women - A 2-year, placebo-controlled study
Authors: de Valk-de Roo, GW Stehouwer, CDA Meijer, P Mijatovic, V Kluft, C Kenemans, P Cohen, F Watts, S Netelenbos, C
Citation: Gw. De Valk-de Roo et al., Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women - A 2-year, placebo-controlled study, ART THROM V, 19(12), 1999, pp. 2993-3000
Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens
Authors: Mijatovic, V van der Mooren, MJ Kenemans, P de Walk-de Roo, GW Netelenbos, C
Citation: V. Mijatovic et al., Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: A randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens, MENOPAUSE, 6(2), 1999, pp. 134-137
CA 125: fundamental and clinical aspects
Authors: Verheijen, RHM von Mensdorff-Pouilly, S van Kamp, GJ Kenemans, P
Citation: Rhm. Verheijen et al., CA 125: fundamental and clinical aspects, SEM CANC B, 9(2), 1999, pp. 117-124
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection
Authors: Mijatovic, V van der Mooren, MJ Stehouwer, CDA Netelenbos, JC Kenemans, P
Citation: V. Mijatovic et al., Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection, GYNECOL END, 13(2), 1999, pp. 130-144
Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer
Authors: Scheele, F Burger, CW Kenemans, P
Citation: F. Scheele et al., Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer, MATURITAS, 33(3), 1999, pp. 191-196
Hormone replacement therapy in women treated for gynaecological malignancy
Authors: Burger, CW van Leeuwen, FE Scheele, F Kenemans, P
Citation: Cw. Burger et al., Hormone replacement therapy in women treated for gynaecological malignancy, MATURITAS, 32(2), 1999, pp. 69-76
Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study
Authors: Kok, ALM Burger, CW van de Weijer, PHM Voetberg, GA Peters-Muller, ERA Kenemans, P
Citation: Alm. Kok et al., Micturition complaints in postmenopausal women treated with continuously combined hormone replacement therapy: a prospective study, MATURITAS, 31(2), 1999, pp. 143-149
Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls
Authors: Snijdewint, FGM von Mensdorff-Pouilly, S Karuntu-Wanamarta, AH Verstraeten, AA van Zanten-Przybysz, I Hummel, P Nijman, HW Kenemans, P Hilgers, J
Citation: Fgm. Snijdewint et al., Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls, CANCER IMMU, 48(1), 1999, pp. 47-55
Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
Authors: van Baal, WM Kenemans, P van der Mooren, MJ Kessel, H Emeis, JJ Stehouwer, CDA
Citation: Wm. Van Baal et al., Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women, THROMB HAEM, 81(6), 1999, pp. 925-928
Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer
Authors: Nijman, HW Kenemans, P Poort-Keesom, RJJ Verstraeten, RA Mensdorff-Pouilly, S Verheijen, RHM Melief, CJM Hilgers, J Meijer, CJLM
Citation: Hw. Nijman et al., Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer, EUR J OB GY, 83(2), 1999, pp. 201-206
Quantification of MUC1 in breast cancer patients - A method comparison study
Authors: Bon, GG van Kamp, GJ Verstraeten, RA von Mensdorff-Pouilly, S Hilgers, J Kenemans, P
Citation: Gg. Bon et al., Quantification of MUC1 in breast cancer patients - A method comparison study, EUR J OB GY, 83(1), 1999, pp. 67-75
Differences between hereditary and sporadic ovarian cancer
Authors: Zweemer, RP Verheijen, RHM Menko, FH Gille, JJP van Diest, PJ Coebergh, JW Shaw, PA Jacobs, IJ Kenemans, P
Citation: Rp. Zweemer et al., Differences between hereditary and sporadic ovarian cancer, EUR J OB GY, 82(2), 1999, pp. 151-153
Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneousovulatory cycles
Authors: Bon, GG Kenemans, P Dekker, JJ Hompes, PG Verstraeten, RA van Kamp, GJ Schoemaker, J
Citation: Gg. Bon et al., Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneousovulatory cycles, HUM REPR, 14(2), 1999, pp. 566-570
Homocysteine and fibrinolysis in acute occlusive coronary events
Authors: van der Mooren, MJ Kenemans, P
Citation: Mj. Van Der Mooren et P. Kenemans, Homocysteine and fibrinolysis in acute occlusive coronary events, LANCET, 354(9188), 1999, pp. 1475-1475
Hormone replacement therapy
Authors: Grant, C Gray, A Paoletti, R Thornton, H von Kleist, S Beral, V Burger, H Creasman, W Delmas, P Kenemans, P Leake, RE Meade, TW Skoog, I Andrews, WC Autier, P Birkhauser, M Fugh-Berman, A Bush, T Calle, E Franceschi, S Holmberg, L Stampfer, M Trimble, E Duffy, S Robertson, C Walker, AM Boyle, P Benagiano, G Horton, R Radda, G Sharp, D Cucinotta, S Castelli, M Manenti, S Monticelli, C Kahle, M Russell-Edu, W Sabatini, C Veronesi, U
Citation: C. Grant et al., Hormone replacement therapy, LANCET, 354(9173), 1999, pp. 152-155
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study
Authors: Nobbenhuis, MAE Walboomers, JMM Helmerhorst, TJM Rozendaal, L Remmink, AJ Risse, EKJ van der Linden, HC Voorhorst, FJ Kenemans, P Meijer, CJLM
Citation: Mae. Nobbenhuis et al., Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study, LANCET, 354(9172), 1999, pp. 20-25
Risultati: 1-25 | 26-50 | 51-59